Community Practice Connections: Optimizing Recognition and Management of Acute Hepatic Porphyria
Released On
December 21, 2022
Expires On
December 21, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Gastroenterology, Primary Care
Topic(s)
Rare Diseases
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward hepatologists and gastroenterologists. Nurses, specialty nurse practitioners, physician assistants, and other clinicians involved in the management of patients with liver diseases are invited to attend.
Program Overview
Acute hepatic porphyria (AHP) is a rare genetic disease caused by enzymatic defects that result in the accumulation of toxic intermediates in the liver. Because AHP symptoms are nonspecific, they are often misdiagnosed as symptoms of other more common conditions. AHP management includes treatment of acute attacks, prevention of attacks, and monitoring for long-term complications.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a symposium held at AASLD: The Liver Meeting in November 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with AHP, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives
- Describe the pathophysiology of AHP, including therapeutic targets
- Apply current assessment strategies to accurately diagnose patients with AHP based on clinical presentation
- Evaluate the efficacy and safety of clinical trial data of current AHP therapies
Faculty
Angelika Ludtke Erwin, MD, PhD
Center for Personalized Genetic Healthcare
Cleveland Clinic
Cleveland, OH
Brendan M. McGuire, MD, MS
Professor of Medicine and Medical Director of the Liver Transplant Program
University of Alabama at Birmingham
Birmingham, AL
Manish Thapar, MD, FACG, FAASLD
Associate Professor of Medicine
Director, Jefferson Center for Genetic and Metabolic Liver Disease
Division of Gastroenterology and Hepatology
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Angelika Ludtke Erwin, MD, PhD
- Consultant: Alnylam, Disc Medicine, Mitsubishi Tanabe, Recordati, Sanofi.
- Brendan M. McGuire, MD, MS
- Grant/Research Support: Arrowhead Pharmaceuticals, Inc; Disc Medicine; Mitsubishi Tanabe Pharma America, Inc.
- Consultant: Alnylam Pharmaceuticals, Inc.
- Manish Thapar, MD, FACG, FAASLD
- Grant/Research Support: Alnylam Pharmaceuticals, Inc; Disc Medicine; Mitsubishi Tanabe Pharma America, Inc.
- Consultant: Alnylam Pharmaceuticals, Inc.
- Speakers’ Bureau: Alnylam Pharmaceuticals, Inc; Disc Medicine; Mitsubishi Tanabe Pharma America, Inc, Recordati.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
AHC Media LLC, freeCME.com • P.O. Box 550669 • Atlanta GA, 30326 • 1-800-688-2421
Copyright © 2004-Present. All rights reserved.
Privacy Policy |
Terms of Use
Design, CMS, Hosting & Web Development ::
ePublishing
Powered by the Rievent Platform™ ::
Rievent Technologies
© Copyright 2017 Rievent Technologies. All rights reserved. Powered by the Rievent Platform™.